03/26/2026
📢SAVE THE DATE! Positioning Psychedelic Assets for Partnership & Acquisition
✨Join us for an engaging panel discussion featuring leaders from the forefront of psychedelic drug development, deal-making, and regulatory strategy. Our panelists bring firsthand experience from both sides of recent landmark transactions, including the $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ asset by AbbVie and the strategic acquisition of Psilera’s portfolio by ataiBeckley.
đź”—https://lnkd.in/gTY3PTBN
đź“…APRIL 08 | 5:00 - 8:00 PM PDT
đź“Ť10918 Technology Pl, San Diego, CA 92127
Key topics will include:
🔸What makes a psychedelic asset attractive to pharma and large biotech
🔸Lessons learned from recent high-profile deals
🔸The critical role of regulatory strategy in enabling successful partnerships and acquisitions
🔸Practical advice for startups and researchers preparing for partnership or exit
Panelists include:
🎤Adam Klein, Ph.D., Senior Scientist, Gilgamesh Pharmaceuticals (in-person)
🎤Jackie von Salm, PhD, Chief Scientific Officer, Psilera (virtual)
🎤Odette Hauke, Regulatory Affairs Consultant (Odette Alina LLC, formerly of ataiBeckley; in-person)
Moderated by:
🎤Kimberly Chew, Senior Counsel and Co-Leader, Psychedelics and Emerging Therapies Practice, Husch Blackwell LLP
